Ocular Therapeutix (NASDAQ:OCUL) Rating Lowered to Sell at Zacks Investment Research

Ocular Therapeutix (NASDAQ:OCUL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Zacks.com reports. According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its […]

Related Keywords

Bedford ,Massachusetts ,United States ,Piper Sandler ,Hikari Power Ltd ,Zacks Investment Research ,Ahrens Investment Partners ,Provident Investment Management Inc ,Nasdaq ,Ocular Therapeutix Inc ,Ocular Therapeutix ,Get Rating ,Investment Partners ,Investment Management ,Bridge Advisors ,Power Ltd ,Resure Sealant ,Nasdaq Ocul ,Hocul ,Medical ,Downgrade ,